Xcellon Biologics and IntoCell are in an extensive, purpose-built partnership

Announcement

IntoCell Inc., a leading biotechnology company establishing linker technologies and next-generation payload for antibody-drug conjugates (ADCs) and Xcellon Biologics, a known US contract development and manufacturing organisation (CDMO), an excellence holder in critical biologics and ADCs, have signed a partnership agreement to bolster ADC manufacturing and development. Alongside, the collaboration will also help extend the reach to next-generation ADC technologies. With this partnership, IntoCell’s exclusive OHPAS drug-combiner platform involving Nexatecan and Duocarmycin-based payloads will be unified into Xcellon Biologics’ ADC development toolbox.

The Xcellon will deliver bioconjugation, ADC manufacturing and development services to further contribute to pharmaceutical and biotech companies. This will optimise IntoCell’s technologies as a piece of their development programs. The collaboration focuses on elevating access to creative ADC technologies by merging IntoCell’s robust chemistry platform with Xcellon’s CDMO infrastructure and potential in the United States.

This alliance stimulates and contributes to the missions of both companies. This allows reach to development potential and high-quality ADC technologies. This has paved a new pathway to walk from discovery to manufacturing. The collaboration will meet fruition if the extensive approach flourishes in the ADC therapies via ADC technologies effectively. This uncovers a new pathway for development and advancement into the ADC therapies by overcoming severity.

Statements from the healthcare leaders

The CEO of IntoCell, Tae Kyo Park, said, “We are grateful to partner with Xcellon Biologics, a known CDMO company. We promise the mutual success starring both companies by merging specific required areas of expertise. By adding IntoCell’s exclusive OHPAS combiner and payload platforms with Xcellon’s manufacturing and bioconjugation expertise, we focus on introducing global innovators with the tools and the required support to get differentiated ADC therapies quickly to the patient population.”

The Board Member of Xcellon Biologics, Abhishek Chhibber, said, “Our missionary vision is to position Xcellon as a ‘one-stop shop’ for the critical biologics and the early development of ADCs. Collaborating with IntoCell has fuelled the vision by enabling us to offer state-of-the-art combiner-payload technologies to our clients within a US-based flexible development framework.”

The Co-Founder and COO of Xcellon Biologics, Yuk Chiu, said, “This partnership improves Xcellon’s ADC toolbox and allows our clients to discover a vast range of payload-combiner alliances specifically and efficiently. By unifying IntoCell’s technologies into our platform, we can leverage timelines and extend the innovation opportunities for next-generation ADC programs.”